Korea University Guro Hospital Bone Defect/Disease Fusion Treatment Center,
Designated as a Hospital Specialization Research Center by the Ministry of Health and Welfare

Accelerating the development of patient-customized artificial bones that are more realistic than real
7 billion KRW will be invested over the next 5 years, focusing on the global market through the development and commercialization of medical devices

The Bone Defect/Disease Fusion Treatment Center (Director Hae-Ryong Song) of Korea University Guro Hospital has been designated as a Hospital Specialization Research Center by the Ministry of Health and Welfare.

The Bone Defect/Disease Fusion Treatment Center announced that it will embark on full-scale research activities to treat the four major orthopedic diseases: limb and spine fractures, osteomyelitis, artificial joints, and bone tumors.

By 2015, patient-customized artificial scaffolds will be developed and commercialized in stages to promote bone formation ability and functional cell fusion, including growth factor-coated implants, osteomyelitis treatment artificial supports with antibiotics, bone regeneration artificial supports with growth factors, and bone regeneration artificial supports with antibiotics and growth factors.

To this end, the center will focus on investing a total project cost of 7 billion KRW, including 5 billion KRW in government subsidies, 1 billion KRW from CowellMedi, and 1 billion KRW from Samjin Pharmaceutical, over the next 5 years.

Professor Hae-Ryong Song (Orthopedic Surgery), Director of the Bone Defect/Disease Fusion Treatment Center at Korea University Guro Hospital, pointed out, "As the world enters an era of super-aging, the global medical industry market for bone defects and diseases will reach 52 trillion KRW in 2015," and said, "As the market has great growth potential, it will become a blue ocean that contributes to the future development of the national medical industry."

He continued, "Our greatest strength is that rapid development and commercialization are possible in connection with the medical device clinical trial center, along with world-class clinical and research capabilities and the establishment of the largest clinical database for intractable bone diseases." He emphasized, "We will build international competitiveness to lower the dependence on overseas medical devices and boldly challenge the global market."

Meanwhile, the Hospital Specialization Research Center is a large-scale national support research project conducted by the Ministry of Health and Welfare to intensively foster the most competitive specialized fields of each hospital and recreate the brand value of the hospital.

The Fusion Treatment Center for Bone Defect/Disease of Korea University Guro Hospital was designated as the National Hospital Specialization Research Center by the Ministry of Health and Welfare.

The Bone Defect/Disease Fusion Treatment Center will start research activities in order to develop new fusion methods for the four major OS issues: limb and spine fractures, osteomyelitis, artificial joints, and bone tumors.

It is planned to develop and commercialize custom-made artificial scaffold (bone substitute) to encourage bone formation capability and functional cell fusion such as an implant coated with growth factors, an artificial scaffold for the treatment of osteomyelitis with mounted antibiotics, an artificial scaffold for osteogenesis with mounted growth factors, an artificial scaffold for osteogenesis with mounted antibiotics and growth factors, etc. in steps until 2015.

Professor Hae-Ryong Song, the Director of the Bone Defect/Disease Fusion Treatment Center of Korea University Guro Hospital, indicated, “As the world enters into a time with a large number of elderly, the size of the foreign medical industry market for bone defect/disease will reach 52 trillion KRW in 2015,” and said, “As the market growth potential is large, the market will be the blue ocean which can support the national medical industry development in the future.”

He said, “Our strongest point is that world-class clinical and research capabilities and the largest clinical database for inveterate bone diseases is provided and that prompt development and commercialization is possible in connection with the medical device clinical center,” and emphasized, “We will have international competitiveness in order to reduce the foreign dependence of domestic medical devices and challenge the world markets in an imposing manner.”